Meeting program

3rd EHA-Balkan Hematology Day - Novel Therapies of Lymphoma

09:00 - 09:15 EET Opening remarks

  • D Coriu, European Hematology Association & Romanian Society of Hematology
  • M Pagoni, Hellenic Society of Haematology
  • I Baltadakis, Hellenic Society of Haematology
  • E Terpos, Hellenic Society of Haematology

09:15 - 10:45 EET Session 1: Chronic lymphocytic leukemia (CLL) and Indolent Lymphomas

Chairs to be announced

  • State-of-the Art: Chronic lymphocytic leukemia (CLL): Selection of The Optimal First-line Treatment
    K Stamatopoulos (Greece)
  • First-line therapy of Chronic lymphocytic leukemia (CLL)
    S Sachanas (Greece)
  • Relapsed Follicular Lymphoma (FL): Current and Emerging Therapies
    E Spanoudakis (Greece)
  • Richter’s Transformation: Which are the Therapeutic Options?
    F Gashi (Kosovo)

10:45 - 11:00 EET Coffee break

11:00 - 12:30 EET Session 2: Aggressive Non-Hodgkin Lymphomas

Chairs to be announced

  • State-of-the Art: Novel Off-the-Self Immunotherapies for Diffuse large B-cell lymphoma (DLBCL) 
    B Ferhanoğlu (Turkey)
  • Primary CNS Lymphoma: Is Autologous Transplantation Beneficial?
    K Venkov (Bulgaria)
  • Front-line Therapy for Double and Triple-Hit Lymphomas
    OD Preda (Romania)
  • Peripheral T cell Lymphomas: The Role of Transplantation
    A Cili (Albania)

12:30 - 13:30 EET Lunch

13:30 - 15:00 EET Session 3: CAR-T Cell Therapies

Chairs to be announced

  • State-of-the Art: CAR-T Cell Therapy in Lymphomas
    I Baltadakis (Greece)
  • CAR-T in Diffuse large B-cell lymphoma (DLBCL) 
    M Sever (Slovenia)
  • CAR-T and the treatment of Mantle Cell Lymphoma (MCL)
    S Bašić-Kinda (Croatia)
  • CAR-T in Follicular Lymphoma (FL)
    S Ratip (Turkey)

15:00 - 15:15 EET Coffee break

15:15 - 16:45 EET Session 4: Hodgkin’s Lymphoma (HL)

Chairs to be announced

  • State-of-the Art: First-Line Therapy of Hodgkin's Lymphoma (HL): The Role of Novel Agents
    T Vassilakopoulos (Greece)
  • The role of Interim PET
    A Agathocleous (Cyprus)
  • Prioritizing Therapeutic Options for Primary Refractory Hodgkin's Lymphoma (HL)
    S Buruiana (Moldova)
  • Management of Relapsed Hodgkin's Lymphoma (HL) After Autologous Transplantation
    M Tsirogianni (Greece)

 16:45 - 17:00 EET Closing remarks